Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00566-2
Affiliations:
31
Authors:
28
Go to article
Institutions Authors Share
Bristol-Myers Squibb, United States of America (USA)
7.000000
 0.25
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
 0.04
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)
1.000000
 0.04
Studienpraxis Urologie, Germany
1.000000
 0.04
TUM University Hospital Klinikum rechts der Isar (MRI), Germany
1.000000
 0.04
Fudan University Shanghai Cancer Center (FUSCC), China
1.000000
 0.04
Hunan Cancer Hospital, China
1.000000
 0.04
Instituto Oncológico de Córdoba (IONC), Argentina
1.000000
 0.04
Hospital Universitario 12 de Octubre, Spain
1.000000
 0.04
Centrum Onkologii, Poland
1.000000
 0.04
Nicolaus Copernicus Provincial Hospital in Koszalin, Poland
1.000000
 0.04
Hospital Universitario Ramón y Cajal, Spain
1.000000
 0.04
Hospital Sirio Libanés, Argentina
1.000000
 0.04
University Hospitals of Strasbourg (HUS), France
1.000000
 0.04
Centro Integrado de Oncologia de Curitiba (CIONC), Brazil
1.000000
 0.04
Hospital of the University of Montreal (CHUM), Canada
1.000000
 0.04
The University of Osaka (UOsaka), Japan
1.000000
 0.04
Icon Group, Australia
0.500000
 0.02
Queensland University of Technology (QUT), Australia
0.500000
 0.02
Victor Hugo Clinic, France
0.500000
 0.02
Centre Jean Bernard, France
0.500000
 0.02
Thomayer Hospital (TN), Czech Republic
0.500000
 0.02
Charles University (CU), Czech Republic
0.500000
 0.02
İzmir University of Economics, Turkey
0.500000
 0.02
Medical Point Hospital, Turkey
0.500000
 0.02
Institute Gustave-Roussy (IGR), France
0.500000
 0.02
Centre Oscar Lambret, France
0.500000
 0.02
Interested in Oncology and Carcinogenesis?